Limitations, agreements, and source contact

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL · Source last updated 2026-05-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

point Of Contact

email

philippe_armand@dfci.harvard.edu

organization

Dana-Farber Cancer Institute

phone

617-632-2305

title

Philippe Armand, MD, PhD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice